Humacyte (HUMA) Gains from Investment Securities (2020 - 2026)

Humacyte (HUMA) has 7 years of Gains from Investment Securities data on file, last reported at $17.3 million in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $17.3 million, up 2420.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $17.3 million (up 542.85% YoY), and the FY2025 annual result was $18.0 million, up 46.69% from the prior year.
• Gains from Investment Securities improved to $17.3 million in Q1 2026 per HUMA's latest filing, from -$74.4 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $25.6 million in Q2 2024 and troughed at -$74.4 million in Q4 2025.
• A 5-year average of -$6.7 million and a median of $687000.0 in 2025 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2024 and 2026: Gains from Investment Securities plunged 485.34% in 2024, then jumped 2420.45% in 2026.
• A 5-year view of Gains from Investment Securities shows it stood at -$17.2 million in 2022, then soared by 158.44% to $10.0 million in 2023, then sank by 485.34% to -$38.7 million in 2024, then plunged by 92.55% to -$74.4 million in 2025, then soared by 123.26% to $17.3 million in 2026.
• Business Quant data shows HUMA's Gains from Investment Securities at $17.3 million in Q1 2026, -$74.4 million in Q4 2025, and -$4.9 million in Q3 2025.